Morbidity and Mortality Weekly Report (MMWR)
The Morbidity and Mortality Weekly Report (MMWR) series are CDC’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. The MMWR series includes the following publications: MMWR Weekly, MMWR Recommendations and Reports, CDC Surveillance Summaries and MMWR Supplements. These journals are freely available to the public as Diamond Open Access. For more on MMWR, visit https://www.cdc.gov/mmwr/index.html.
Select all docs (Max 200)
Narrow Results:
Volume
Series
Publication Year
Medical Subject
- 2019-nCoV Vaccine mRNA-1273 2
- Acute Disease 1
- Ad26COVS1 1
- Adolescent 11
- Adult 9
- Adverse Drug Reaction Reporting Systems 12
- Adverse Event 1
- Advisory Committees 2
- Aged 8
- Aged, 80 and over 3
- Animals 1
- Antigens, Viral / immunology 1
- Antiviral Agents / administration & dosage 1
- Antiviral Agents / therapeutic use 5
- Anxiety 2
- Anxiety-related Reaction 1
- Arrhythmias, Cardiac 1
- Articles 1
- BNT162 Vaccine 5
- BNT162 Vaccine / Adverse Effects 1
- Centers for Disease Control and Prevention, U.S. 1
- Child 8
- Child, Preschool 5
- Cluster Analysis 1
- Contraindications 1
- CoronaVirus Infections 4
- CoronaVirus Infections/Prevention & Control 6
- Cost of Illness 1
- COVID-19 9
- COVID-19 Vaccines 18
- COVID-19 Vaccines/ 1
- COVID-19 Vaccines/adverse effects 1
- COVID-19 Vaccines/adverse reactions 1
- COVID-19/epidemiology 1
- COVID-19/Prevention & Control 5
- COVID-19/prevention & control 1
- Delivery of Health Care, Integrated 1
- Disease Outbreaks / prevention & control 5
- Drug-Related Side Effects and Adverse Reactions 4
- Drug Approval 1
- Female 12
- Guidelines as Topic 1
- Humans 15
- Immunization 1
- Immunization, Secondary 6
- Immunization Programs 1
- Immunization Schedule 1
- Immunocompromised Host 1
- Infant 4
- Infant, Newborn 2
- Influenza, Human 1
- Influenza, Human / complications 1
- Influenza, Human / drug therapy 5
- Influenza, Human / epidemiology 2
- Influenza, Human / prevention & control 3
- Influenza, Human / transmission 1
- Influenza / drug therapy 1
- Influenza A virus 4
- Influenza A Virus, H1N1 Subtype 2
- Influenza A Virus, H1N1 Subtype / immunology 1
- Influenza A Virus, H3N2 Subtype 2
- Influenza A Virus, H3N2 Subtype / immunology 1
- Influenza B virus 5
- Influenza B virus / immunology 1
- Influenza Vaccines 1
- Influenza Vaccines / administration & dosage 6
- Influenza Vaccines / adverse effects 2
- Influenza Vaccines / immunology 1
- Influenza Vaccines / supply & distribution 1
- Male 12
- Mass Vaccination 6
- Mass Vaccination/Psychology 1
- Middle Aged 9
- Mortality 1
- mRNA Vaccines 3
- Myocarditis 3
- Patient Safety 3
- Pericarditis 2
- Pneumococcal Vaccines / administration & dosage 1
- Pneumococcal Vaccines / adverse effects 1
- Population Surveillance 2
- Post-Exposure Prophylaxis 1
- Pregnancy 1
- Product Surveillance, Postmarketing 3
- Respiratory Tract Infections 1
- Risk 1
- Risk Assessment 3
- RNA, Messenger 2
- Safety 3
- Safety-Based Drug Withdrawals 1
- SARS-CoV-2 5
- Seasons 2
- Seizures, Febrile / etiology 1
- Sinus Thrombosis, Intracranial 1
- Syncope 1
- Vaccination 6
- Vaccination / standards 4
- Vaccines 2
- Vaccines, Synthetic 3
- Young Adult 5
Personal Author
- Shay, David K. (29)
Corporate Author
- CDC COVID-19 Emergency Response Team 2
- CDC COVID-19 Emergency Response Team. 1
- CDC COVID-19 Response Team 1
- CDC COVID-19 Response Team. 4
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle Children’s Hospital, Seattle, Washington 1
- Center for Health Research (Kaiser-Permanente Medical Care Program. Northwest Region) 1
- Centers for Disease Control and Prevention (U.S.) 6
- Centers for Disease Control and Prevention (U.S.), Office of the Associate Director for Science. 1
- Centers for Disease Control and Prevention (U.S.). Immunization Safety Office. 3
- Centers for Disease Control and Prevention (U.S.)Epidemic Intelligence Service. 1
- Children’s Healthcare of Atlanta. 1
- Children’s Hospital of Philadelphia. Applied Clinical Research Center. Department of Pediatrics. 1
- Fenway Institute. 1
- Harvard Pilgrim Health Care Institute. Department of Population Medicine. 1
- HealthPartners Institute (Minneapolis, Minnesota) 1
- Institute for Health Research (Kaiser Permanente Colorado) 1
- Kaiser-Permanente Medical Care Program. Southern California Region. Research and Evaluation. 1
- Kaiser Permanente Vaccine Study Center. 1
- Lewis Katz School of Medicine. Department of Medicine. 1
- Louisiana Public Health Institute. 1
- Marshfield Clinic Research Institute. 1
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. 1
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.)Immunization Safety Office. 1
- National Center for Immunization and Respiratory Diseases (U.S.) 4
- National Center for Immunization and Respiratory Diseases (U.S.), Immunization Services Division. 1
- National Center for Immunization and Respiratory Diseases (U.S.), Influenza Division. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. 3
- National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. 4
- National Center for Preparedness, Detection, and Control of Infectious Diseases (U.S.), Division of Healthcare Quality Promotion., Immunization Safety Office. 1
- National Patient-Centered Clinical Research Network. 1
- Nemours Children’s Health System. Nemours Cardiac Center. 1
- OCHIN, Inc. 1
- Stanford University School of Medicine. Department of Pediatrics. 1
- U.S. Food and Drug Administration 2
- United States. Advisory Committee on Immunization Practices. 7
- United States Food and Drug Administration. 1
- University of North Carolina at Chapel Hill. School of Medicine. Center for Gastrointestinal Biology and Disease. 1
- University of Texas Southwestern Medical Center at Dallas. Department of Population and Data Sciences and Department of Immunology. 1
Place as Subject
- Colorado 1
- Florida 1
- Iowa 1
- Kansas 1
- Louisiana 1
- Maryland 1
- Michigan 1
- Missouri 1
- Nebraska 1
- New York 1
- North Carolina 1
- Ohio 1
- Pennsylvania 1
- South Carolina 1
- Tennessee 1
- Texas 1
- U.S. 6
- United States 12
- Utah 1
- Wisconsin 1
Resource Type General
Resource Type Specific
x
Shay, David K.
Select all docs
(Max 200)
(Max 200)
1 -
20 of 29 Results
SELECT A RANGE
SELECT A FORMAT
Refine Results
Refine Results:
- 2019-nCoV Vaccine mRNA-1273 (2)
- Acute Disease (1)
- Ad26COVS1 (1)
- Adolescent (11)
- Adult (9)
- Adverse Drug Reaction Reporting Systems (12)
- Adverse Event (1)
- Advisory Committees (2)
- Aged (8)
- Aged, 80 and over (3)
- Animals (1)
- Antigens, Viral / immunology (1)
- Antiviral Agents / administration & dosage (1)
- Antiviral Agents / therapeutic use (5)
- Anxiety (2)
- Anxiety-related Reaction (1)
- Arrhythmias, Cardiac (1)
- Articles (1)
- BNT162 Vaccine (5)
- BNT162 Vaccine / Adverse Effects (1)
- Centers for Disease Control and Prevention, U.S. (1)
- Child (8)
- Child, Preschool (5)
- Cluster Analysis (1)
- Contraindications (1)
- CoronaVirus Infections (4)
- CoronaVirus Infections/Prevention & Control (6)
- Cost of Illness (1)
- COVID-19 (9)
- COVID-19 Vaccines (18)
- COVID-19 Vaccines/ (1)
- COVID-19 Vaccines/adverse effects (1)
- COVID-19 Vaccines/adverse reactions (1)
- COVID-19/epidemiology (1)
- COVID-19/Prevention & Control (5)
- COVID-19/prevention & control (1)
- Delivery of Health Care, Integrated (1)
- Disease Outbreaks / prevention & control (5)
- Drug-Related Side Effects and Adverse Reactions (4)
- Drug Approval (1)
- Female (12)
- Guidelines as Topic (1)
- Humans (15)
- Immunization (1)
- Immunization, Secondary (6)
- Immunization Programs (1)
- Immunization Schedule (1)
- Immunocompromised Host (1)
- Infant (4)
- Infant, Newborn (2)
- Influenza, Human (1)
- Influenza, Human / complications (1)
- Influenza, Human / drug therapy (5)
- Influenza, Human / epidemiology (2)
- Influenza, Human / prevention & control (3)
- Influenza, Human / transmission (1)
- Influenza / drug therapy (1)
- Influenza A virus (4)
- Influenza A Virus, H1N1 Subtype (2)
- Influenza A Virus, H1N1 Subtype / immunology (1)
- Influenza A Virus, H3N2 Subtype (2)
- Influenza A Virus, H3N2 Subtype / immunology (1)
- Influenza B virus (5)
- Influenza B virus / immunology (1)
- Influenza Vaccines (1)
- Influenza Vaccines / administration & dosage (6)
- Influenza Vaccines / adverse effects (2)
- Influenza Vaccines / immunology (1)
- Influenza Vaccines / supply & distribution (1)
- Male (12)
- Mass Vaccination (6)
- Mass Vaccination/Psychology (1)
- Middle Aged (9)
- Mortality (1)
- mRNA Vaccines (3)
- Myocarditis (3)
- Patient Safety (3)
- Pericarditis (2)
- Pneumococcal Vaccines / administration & dosage (1)
- Pneumococcal Vaccines / adverse effects (1)
- Population Surveillance (2)
- Post-Exposure Prophylaxis (1)
- Pregnancy (1)
- Product Surveillance, Postmarketing (3)
- Respiratory Tract Infections (1)
- Risk (1)
- Risk Assessment (3)
- RNA, Messenger (2)
- Safety (3)
- Safety-Based Drug Withdrawals (1)
- SARS-CoV-2 (5)
- Seasons (2)
- Seizures, Febrile / etiology (1)
- Sinus Thrombosis, Intracranial (1)
- Syncope (1)
- Vaccination (6)
- Vaccination / standards (4)
- Vaccines (2)
- Vaccines, Synthetic (3)
- Young Adult (5)
- CDC COVID-19 Emergency Response Team (2)
- CDC COVID-19 Emergency Response Team. (1)
- CDC COVID-19 Response Team (1)
- CDC COVID-19 Response Team. (4)
- Center for Child Health, Behavior and Development, Seattle Children’s Research Institute, Seattle Children’s Hospital, Seattle, Washington (1)
- Center for Health Research (Kaiser-Permanente Medical Care Program. Northwest Region) (1)
- Centers for Disease Control and Prevention (U.S.) (6)
- Centers for Disease Control and Prevention (U.S.), Office of the Associate Director for Science. (1)
- Centers for Disease Control and Prevention (U.S.). Immunization Safety Office. (3)
- Centers for Disease Control and Prevention (U.S.)Epidemic Intelligence Service. (1)
- Children’s Healthcare of Atlanta. (1)
- Children’s Hospital of Philadelphia. Applied Clinical Research Center. Department of Pediatrics. (1)
- Fenway Institute. (1)
- Harvard Pilgrim Health Care Institute. Department of Population Medicine. (1)
- HealthPartners Institute (Minneapolis, Minnesota) (1)
- Institute for Health Research (Kaiser Permanente Colorado) (1)
- Kaiser-Permanente Medical Care Program. Southern California Region. Research and Evaluation. (1)
- Kaiser Permanente Vaccine Study Center. (1)
- Lewis Katz School of Medicine. Department of Medicine. (1)
- Louisiana Public Health Institute. (1)
- Marshfield Clinic Research Institute. (1)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. (1)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.)Immunization Safety Office. (1)
- National Center for Immunization and Respiratory Diseases (U.S.) (4)
- National Center for Immunization and Respiratory Diseases (U.S.), Immunization Services Division. (1)
- National Center for Immunization and Respiratory Diseases (U.S.), Influenza Division. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. (3)
- National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. (4)
- National Center for Preparedness, Detection, and Control of Infectious Diseases (U.S.), Division of Healthcare Quality Promotion., Immunization Safety Office. (1)
- National Patient-Centered Clinical Research Network. (1)
- Nemours Children’s Health System. Nemours Cardiac Center. (1)
- OCHIN, Inc. (1)
- Stanford University School of Medicine. Department of Pediatrics. (1)
- U.S. Food and Drug Administration (2)
- United States. Advisory Committee on Immunization Practices. (7)
- United States Food and Drug Administration. (1)
- University of North Carolina at Chapel Hill. School of Medicine. Center for Gastrointestinal Biology and Disease. (1)
- University of Texas Southwestern Medical Center at Dallas. Department of Population and Data Sciences and Department of Immunology. (1)
- :Smith, Nicole M. ;Bresee, Joseph S.July 28, 2006 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):"This report updates the 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and an...:superseded
- :Bresee, Joseph S. ;Cox, Nancy (Nancy J.)July 13, 2007 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):"This report updates the 2006 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and ...:superseded
- :Bresee, Joseph S. ;Broder, Karen R.August 8, 2008 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):"This report updates the 2007 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and ...:superseded
- :Bresee, Joseph S. ;Broder, Karen R.July 31, 2009 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):This report updates the 2008 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine for t...:superseded
- :Bresee, Joseph S. ;Broder, Karen R.August 6, 2010 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):"This report updates the 2009 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine for ...:superseded
- :Bresee, Joseph S. ;Fiore, Anthony E.January 21, 2011 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):"This report updates previous recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of antiviral agents for t...:current
- :Jackson, Lisa ;Jackson, Michael L.Jan 18 2013 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months. Each season since 2004-05, CDC ha...
- :Grohskopf, Lisa A. ;Shay, David K.September 20, 2013 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR):This report updates the 2012 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for ...:superseded
- :Hause, Anne M. ;Gee, JulianneJuly 30, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? In preauthorization trials of the Pfizer-BioNTech COVID-19 Vaccine, adolescents aged 12–17 years reported lo...
- :Hause, Anne M. ;Baggs, JamesSeptember 28, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? Among 306 Pfizer-BioNTech clinical trial participants, adverse reactions after dose 3 were similar to those af...
- :Shay, David K. ;Gee, JulianneApril 30, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? An Emergency Use Authorization of the Janssen COVID-19 vaccine was granted February 27, 2021. Use was paused d...
- :Hause, Anne M. ;Gee, JulianneApril 30, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? Syncope and other anxiety-related events can occur after vaccination and have been reported to the Vaccine Adv...
- :Xu, Stanley ;Huang, RunxinOctober 22, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? Although deaths after COVID-19 vaccination have been reported to the Vaccine Adverse Events Reporting System, ...
- :Hause, Anne M. ;Gee, Julianne5 07 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):On April 7, 2021, after 5 weeks' use of the Janssen COVID-19 vaccine under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA), C...
- :Shay, David K. ;Gee, Julianne5 07 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Janssen (Ad.26.COV2.S) COVID-19 vaccine (...
- :Hause, Anne M. ;Gee, Julianne8 06 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):As of July 30, 2021, among the three COVID-19 vaccines authorized for use in the United States, only the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccin...
- :Hause, Anne M. ;Baggs, James10 01 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna Covid-19 Va...
- :Xu, Stanley ;Huang, Runxin10 29 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):By September 21, 2021, an estimated 182 million persons in the U.S. were fully vaccinated against COVID-19.* Clinical trials indicate that Pfizer-BioN...
- :Hause, Anne M. ;Baggs, James12 31 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):On October 29, 2021, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 (BNT162b2) mRNA...
- :Block, Jason P. ;Boehmer, Tegan K.April 1, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? Studies have found an increased risk for cardiac Complications after SARS-CoV-2 infection and mRNA COVID-19 va...
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.